Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Cognitive Focus Stack: Semax + Selank for Brain Research

Back to library
peptide

Cognitive Focus Stack: Semax + Selank for Brain Research

10 min read
RESEARCH STACK
NEUROSCIENCE RESEARCH
COGNITIVE FOCUS STACK
✅ RESEARCH CHEMICAL

Research Use Only. Semax and Selank are sold strictly as research chemicals for in vitro and laboratory study. This article summarises published preclinical and clinical research literature. It does not constitute medical advice, a treatment protocol, or a recommendation for human use.

Cognitive Focus Stack: Semax + Selank Brain Research Overview

The Cognitive Focus Stack combines two Russian-developed neuropeptides whose research profiles represent complementary arms of cognitive biology: Semax drives neurotrophin upregulation and glutamatergic enhancement; Selank modulates GABAergic and serotonergic tone with an anxiolytic-without-sedation profile. Together they address two of the most studied axes of cognitive function — excitatory plasticity (Semax) and inhibitory balance (Selank) — through independent mechanisms that make them scientifically complementary rather than redundant in research design.

Key Takeaways

  • Semax: ACTH(4-7)-Pro-Gly-Pro heptapeptide (CAS: 80714-61-0, MW: ~814 Da) — upregulates BDNF, NGF, activates NMDA and dopamine D1 receptors; Russian Rx nasal spray
  • Selank: tuftsin-derived heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (CAS: 129954-34-3, MW: ~863 Da) — GABA-A positive modulation, serotonin metabolism enhancement; Russian Rx approved
  • Semax increases neural excitability and plasticity; Selank restores inhibitory balance — mechanistically complementary, not competing
  • Both peptides are approved as prescription medicines in Russia (nasal spray formulations); classified as research chemicals outside Russia
  • Combination rationale: Semax-driven BDNF upregulation + Selank-mediated GABAergic balance targets excitatory/inhibitory homeostasis studied in anxiety, cognitive deficit, and neuroprotection models
  • No published human RCT for the Semax + Selank combination specifically — individual compound data is strong preclinically, human data limited
7
Amino Acids
Both Semax and Selank
BDNF
Semax Primary Target
Brain-derived neurotrophic factor
GABA-A
Selank Target
Positive allosteric modulation
2
Russian Rx Approvals
Nasal spray formulations

Research-grade Semax and Selank from Pure Grade Labs — both supplied with full CoA and purity documentation.

View Research Catalogue →

Component 1: Semax — BDNF Upregulation and Glutamatergic Enhancement

Semax (Met-Glu-His-Phe-Pro-Gly-Pro; CAS: 80714-61-0; MW: ~814 Da) is a synthetic heptapeptide derived from ACTH(4-10) — the residues of adrenocorticotropic hormone responsible for its cognitive effects — truncated and extended with a Pro-Gly-Pro stabilising sequence. Originally developed at the Institute of Molecular Genetics in Moscow, Semax was approved in Russia as a nasal spray for ischaemic stroke and cognitive impairment treatment.

The neurobiological mechanisms attributed to Semax in the published literature:

  • BDNF upregulation: Semax administration in rodent models significantly increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus, prefrontal cortex, and cerebellum within hours. BDNF is the primary driver of synaptic plasticity, LTP (long-term potentiation), and neuronal survival — mechanistically linking Semax to memory formation and learning
  • NGF and VEGF induction: Nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) are also upregulated in CNS tissue following Semax exposure in rodent ischaemia models, contributing to neuroprotection and cerebrovascular recovery
  • NMDA receptor activation: Semax potentiates NMDA receptor-mediated currents in hippocampal neurons — directly enhancing glutamatergic excitatory transmission involved in learning and memory encoding
  • Dopamine D1 and D3 receptor interaction: Dopaminergic system modulation has been documented in Semax studies, with prefrontal cortex D1 receptor upregulation observed in stress models — potentially relevant to attention and working memory functions
  • Cholinergic enhancement: Acetylcholinesterase activity modulation in several brain regions has been reported, connecting Semax to the cholinergic system that is centrally impaired in Alzheimer’s disease models

In the context of the cognitive stack, Semax contributes the pro-plasticity, pro-excitatory dimension: increased BDNF drives synaptogenesis and LTP; NMDA enhancement facilitates the Hebbian mechanisms of memory formation. Semax essentially amplifies the brain’s capacity to encode and consolidate information at the synaptic level.

Component 2: Selank — GABAergic Balance and Anxiolytic-Without-Sedation Profile

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; CAS: 129954-34-3; MW: ~863 Da) is a synthetic analogue of tuftsin, the endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg), with a stabilising Pro-Gly-Pro C-terminal extension. Developed at the Institute of Molecular Genetics and Balabolkin Institute in Moscow, Selank received Russian approval as an anxiolytic and nootropic nasal spray formulation.

Selank’s central mechanisms documented in the preclinical literature:

  • GABA-A positive allosteric modulation: Selank positively modulates GABA-A receptor activity, enhancing GABAergic inhibitory tone across the cortex, limbic system, and amygdala — the primary mechanism of its anxiolytic effect. Critically, this modulation is distinct from benzodiazepines: Selank does not bind the benzodiazepine site on GABA-A and does not produce the muscle relaxation, sedation, or dependence risk associated with BZD pharmacology
  • Serotonin metabolism enhancement: Selank increases the activity of tryptophan hydroxylase and monoamine oxidase in serotonergic pathways, elevating available serotonin in prefrontal and limbic regions — contributing to its anxiolytic and mood-stabilising effects
  • Enkephalin stabilisation: Selank inhibits enkephalin-degrading enzymes (specifically aminopeptidase and dipeptidyl peptidase), extending the activity of endogenous opioid peptides that modulate stress responses and pain
  • IL-6 and immune modulation: As a tuftsin analogue, Selank retains partial immunomodulatory activity — upregulating IL-6 production in T-lymphocytes and modulating innate immune responses. The immunological research context of Selank is distinct from its nootropic applications

Mechanistic Insight — Anxiolytic Without Sedation: The GABA-A modulation profile of Selank is one of its most research-relevant properties. Classical benzodiazepines (diazepam, alprazolam) produce anxiolysis via the benzodiazepine site on GABA-A, but this same mechanism produces sedation, cognitive impairment, motor incoordination, and dependence — all via the same receptor. Selank’s anxiolytic effect operates via a different modulatory site or allosteric mechanism that enhances GABA-A inhibitory tone in limbic regions (amygdala, hippocampus) without the sedative effects on motor and sensory cortex that benzodiazepines produce. In rodent models, Selank reduces open-field anxiety behaviours (reduced freezing, increased exploration) without impairing novel object recognition or maze performance — suggesting anxiolysis without cognitive cost. This profile makes Selank particularly interesting in stress-cognitive performance research: the question of whether reducing anxiety improves cognitive output under stress conditions is cleanly addressable with Selank in a way it would not be with sedating anxiolytics.

Stack Complementarity: Excitatory Plasticity + Inhibitory Balance

The Cognitive Focus Stack’s scientific rationale rests on the E/I balance model of cognitive function — the neurobiological principle that optimal cognitive performance requires balanced excitatory (glutamatergic) and inhibitory (GABAergic) tone. Too much inhibition → reduced plasticity, impaired encoding. Too much excitation → noise, impaired signal discrimination, anxiety-driven cognitive interference. The E/I balance hypothesis predicts that interventions targeting both sides of this balance may produce greater cognitive enhancement than either alone.

Research Axis Semax Selank Stack Logic
Neurotransmitter bias Glutamate ↑ (NMDA) GABA ↑ (GABA-A) E/I balance
Neurotrophin effect BDNF + NGF ↑ Neuroprotective via serotonin Dual neurotrophin support
Anxiety/stress effect Mild activating Anxiolytic (non-sedating) Balanced activation
Memory encoding LTP facilitation Anxiety-reduction → ↑ encoding Convergent via different routes
Regulatory status (UK) Research chemical Research chemical Safe ✅

Clinical Research Context: Stroke, Anxiety, and Cognitive Deficit Models

Both Semax and Selank were developed within the Soviet/Russian pharmaceutical research system and have accumulated clinical experience as approved medicines in Russia — providing a degree of human safety data that purely preclinical research chemicals do not have. This contextualises their research profiles:

Semax in stroke/ischaemia research: Multiple Russian clinical studies (Gusev et al., 1997; Miasoedov et al., 1999) examined Semax in acute ischaemic stroke patients, reporting cognitive recovery improvements versus standard care. The BDNF-upregulation mechanism provides a biologically plausible basis: BDNF is a critical survival factor for neurons in the penumbra (the border zone of ischaemic brain tissue that remains potentially salvageable post-stroke). These studies were conducted under Russian clinical trial standards and have not been replicated in Western RCT frameworks — limiting their global evidential weight while establishing the compound’s human safety profile.

Selank in anxiety research: Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) reported Selank produced anxiolytic effects comparable to diazepam in generalised anxiety disorder patients without cognitive side effects — the key differentiator from BZD standard care. A subsequent 2014 placebo-controlled study (Meshcheryakova et al.) examined Selank in anxiety-phobic disorder, demonstrating statistically significant reductions in Hamilton Anxiety Rating Scale scores versus placebo over 4 weeks.

Research Note — The Pro-Gly-Pro Stabilisation Strategy: Both Semax and Selank share the Pro-Gly-Pro C-terminal extension — a deliberate structural modification made during development to resist enzymatic degradation. Native ACTH(4-7) and tuftsin are both rapidly cleaved by plasma peptidases, giving them biological half-lives measured in seconds to minutes in vivo. Appending Pro-Gly-Pro to the C-terminus provides steric protection from carboxypeptidase attack and reduces the rate of endopeptidase cleavage of the internal sequence. The result is plasma stability of hours rather than seconds — sufficient for nasal spray delivery to produce measurable CNS effects through the olfactory mucosa route. This shared structural strategy, applied independently to two different parent peptides, produced two compounds with very different pharmacological profiles but similar stability characteristics — an elegant example of medicinal chemistry applied to neuropeptide translation.

Preclinical Research Design for the Cognitive Focus Stack

Researchers designing studies with the Semax + Selank combination should consider:

  • Cognitive endpoints: Morris water maze (spatial memory), novel object recognition (recognition memory), Y-maze (working memory), 5-choice serial reaction time task (attention) — all validated in rodent preclinical models for the mechanisms Semax and Selank are proposed to affect
  • Anxiety endpoints: Elevated plus maze, open field test, fear conditioning extinction — validated for GABAergic and anxiolytic interventions
  • Biomarker readouts: Hippocampal BDNF protein (ELISA), BDNF mRNA (qPCR), GABA and glutamate neurotransmitter levels (LC-MS in brain tissue), serotonin metabolite (5-HIAA) in CSF
  • Administration route: Both compounds have been studied intranasally (reflecting the Russian approved formulation) and subcutaneously. Intranasal administration provides direct olfactory-to-brain delivery bypassing the BBB — researchers should specify route in study design as PK profiles differ significantly
  • Dosing timing: Semax’s BDNF induction peaks at ~6–12 hours post-administration in rodent studies; Selank’s anxiolytic effects peak acutely (30–60 min). Sequential timing (Selank before cognitive stress test; Semax as chronic neurotrophin-building protocol) may reflect the complementary temporal pharmacology

Frequently Asked Questions

How do Semax and Selank complement each other in cognitive research?

Semax drives neuroplasticity through BDNF upregulation and NMDA receptor enhancement — increasing the brain’s capacity for synaptic strengthening and memory encoding. Selank reduces anxiety-driven interference through GABA-A modulation, improving signal-to-noise in cognitive processing without sedation. They target different sides of the excitatory/inhibitory balance, making them mechanistically complementary.

Is Selank different from benzodiazepines mechanistically?

Yes — Selank modulates GABA-A receptors through a different mechanism than benzodiazepines. It does not bind the benzodiazepine allosteric site and does not produce benzodiazepine-associated sedation, cognitive impairment, or dependence in preclinical models. The anxiolytic effect is present in limbic/amygdala circuits without the generalised CNS depression that BZDs produce.

What is the human evidence base for Semax and Selank?

Both are approved prescription medicines in Russia with clinical experience across stroke rehabilitation (Semax) and anxiety disorders (Selank). Russian clinical studies report positive findings but were conducted under different regulatory standards than Western RCTs. Neither compound has completed Western-registered Phase III trials. Their human safety profile is better established than many research peptides, but formal Western clinical evidence remains limited.

Why is BDNF important in cognitive research?

Brain-derived neurotrophic factor (BDNF) is the primary molecular mediator of synaptic plasticity and long-term potentiation (LTP) — the cellular basis of learning and memory. BDNF binds TrkB receptors and activates PI3K/Akt/mTOR and MAPK/ERK cascades that promote synaptogenesis, dendritic arborisation, and neuronal survival. Semax-driven BDNF upregulation in the hippocampus directly targets the mechanisms most closely associated with memory formation in preclinical models.

Summary

The Cognitive Focus Stack applies the E/I balance principle to nootropic research: Semax amplifies excitatory plasticity through BDNF/NMDA pathways while Selank restores GABAergic inhibitory balance without sedation. Both peptides have Russian clinical approval establishing basic human safety. The scientific question the combination allows researchers to ask — whether simultaneously enhancing neuroplasticity and reducing anxiety-driven cognitive interference produces greater cognitive effects than either intervention alone — is mechanistically well-reasoned and underexplored in published literature.

Source research-grade Semax and Selank with full CoA from Pure Grade Labs.

Shop Research Chemicals →

References

  1. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in acute period of hemispheric ischemic stroke (a multicenter randomized trial). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26–34. PMID: 9280472
  2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. PMID: 16934229
  3. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new anxiolytic drug Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38–48. PMID: 18454096
  4. Meshcheryakova ES, Andreeva LA, Grivennikov IA, et al. Selank for treatment of anxiety-phobic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):25–29.
  5. Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II. Comparison of the effects of Selank and tuftsin on the behavior and cognitive processes in rats. Eksp Klin Farmakol. 2010;73(8):2–5. PMID: 20886742
  6. Bhargava HN. Multiple opiate receptors of the brain and spinal cord. II. Gen Pharmacol. 1991;22(5):797–800. PMID: 1660754

Disclaimer: This article is published for educational and research purposes only. Semax and Selank are sold by Pure Grade Labs strictly as research chemicals, not for human consumption or therapeutic use. No claims are made regarding efficacy in humans. All research use must comply with applicable institutional and regulatory requirements.